Author:
Nabity Scott A.,Agraz-Lara Rocio,Bravo Angelito,Benjamin Robert,Fong Vanessa,Lam C. Kin,Keh Chris,Mase Sundari,Flood Jennifer
Publisher
Centers for Disease Control MMWR Office
Subject
Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology
Reference5 articles.
1. Interruptions in supplies of second-line antituberculosis drugs—United States, 2005–2012.;CDC;MMWR Morb Mortal Wkly Rep,2013
2. Impact of a shortage of first-line antituberculosis medication on tuberculosis control—United States, 2012–2013.;CDC;MMWR Morb Mortal Wkly Rep,2013
3. Sterling TR, Njie G, Zenner D, Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020;69(No. RR-1):1–11. 10.15585/mmwr.rr6901a132053584
4. Interim guidance: 4-month rifapentine moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis—United States, 2022.;Carr;MMWR Morb Mortal Wkly Rep,2022
5. Tuberculosis—United States, 2022.;Schildknecht;MMWR Morb Mortal Wkly Rep,2023